West Pharma (WST) Tops Q1 EPS by 2c; Boosts Lower-End of FY16 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Nasdaq ticks up as tech stocks steady; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
West Announces First Quarter 2016 Results
April 28, 2016 7:01 AM EDTEXTON, Pa., April 28, 2016 /PRNewswire/ --Â West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the first quarter 2016 and updated financial guidance for the full-year 2016.Â
First Quarter 2016 Highlights
Reported net sales of $362.1 million grew 7.8% over the prior-year quarter. Net sales at constant currency grew by 10.5%. Adjusted operating profit margin of 15.4% increased by 120 basis points over the prior-year quarter. First-quarter 2016... More


